No Data
No Data
Qianjin Pharmaceutical 2024 Semi-Annual Report
Summary of Qianjin Pharmaceutical\'s 2024 Semi-Annual Report
Zhuzhou Qianjin Pharmaceutical (600479.SH) released its performance for the first half of the year, with a net income of 0.118 billion yuan, a year-on-year growth of 0.87%.
Zhuzhou Qianjin Pharmaceutical (600479.SH) released its 2024 interim report, with the company achieving revenue of 1...
Zhuzhou Qianjin Pharmaceutical (600479.SH): the net income in the first half of the year was 11.8 billion yuan, a year-on-year increase of 0.87%.
Geelong reported on August 27th that Zhuzhou Qianjin Pharmaceutical (600479.SH) announced its semi-annual report. During the reporting period, the company achieved revenue of 1.924 billion yuan, a year-on-year increase of 0.6%; total profit of 0.174 billion yuan, a year-on-year increase of 2.71%; and net income attributable to shareholders of the listed company of 0.118 billion yuan, a year-on-year increase of 0.87%.
Zhuzhou Qianjin Pharmaceutical (600479.SH): Has not yet launched its cosmetics business.
Qianjin Pharmaceutical (600479.SH) stated on its investor interaction platform on August 20th that the company has not yet launched beauty and skincare business.
Why You Might Be Interested In ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) For Its Upcoming Dividend
No Data
No Data